ClinicalTrials.gg
CompletedNCT02166788EAGLE FMUpdated May 9, 2025

Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma

A Phase 3 interventional study of Inguinal Lymphadenectomy and Ilio-inguinal Lymphadenectomy in Metastatic Melanoma to the Groin Lymph Nodes, sponsored by Melanoma and Skin Cancer Trials Limited. Completed at 17 sites in 6 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by Melanoma and Skin Cancer Trials Limited · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
634
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited — 2 open to participants now, 4 under way, none of them phase 3. Melanoma · Melanoma and Skin Cancer Trials Limited.

Planned enrollment
3rd of 10
634 · median 210
Started
2015
with 2 others
Phase 3
Only one
of the 10
Registered
4th of 10
by date

Among the 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2015, is the only one in phase 3, and was the 4th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Melanoma by Melanoma and Skin Cancer Trials Limited, or all of them as a file.
02

Study summary

BACKGROUND: Spread of metastatic melanoma to the groin lymph nodes (LN) is a common event affecting about 350 people a year in Australia. Globally it has been shown that patients with involved groin LN, without proven pelvic LN disease on imaging receive 1 of 3 management strategies in equal proportions - inguinal lymphadenectomy (IL); ilio-inguinal lymphadenectomy (I-IL); or variable use of either depending on circumstances. Different experts have strong and polarised opinions favouring either IL or more extensive I-IL with existing cases series reporting conflicting data on best cancer outcomes. No high level evidence proves which operation is best. HYPOTHESIS: There will be no significant difference in DFS between patients having IL or I-IL, conditional on PET/CT scan showing no evidence of pelvic disease at the time of diagnosis of groin LN metastatic melanoma. AIMS: To provide a rational evidence base for management for melanoma to the groin LNs by randomly assessing the effect of each operation on DFS, distant DFS, overall survival (OS), morbidity - including early complications and longer-term rates of lymphedema as well as comprehensively assessed QOL. Also to clarify the reliability of PET/CT scans for staging pelvic LNs and evaluate any health economic benefits of I-IL over IL. TARGET POPULATION: To recruit 634 patients in 5 years. DESIGN: An Australian led, international, multi-centre, non-inferiority, phase III, prospective, randomised clinical trial comparing IL or I-IL for patients with metastatic melanoma to groin LNs and no evidence of pelvic disease on PET/CT. ENDPOINTS: DFS, Distant DFS, OS and QOL at 5 years. Accuracy of PET/CT for pelvic LN metastases.

OUTCOMES: International standardization of care, improved cancer outcomes, improved QOL for patients with groin metastatic melanoma. Proof of principle about extent of surgery when PET/CT is clear in adjacent LN areas, leading to clinical trials investigating management of other lymph node fields.

Read the detailed description

Background and Rationale

Spread of metastatic melanoma to the groin lymph nodes (LN) is a common event for patients with melanoma. In melanoma treatment centres around the world, patients without demonstrated pelvic LN disease receive 1 of 3 strategies of management in relatively equal proportions (Pasquali, Spillane et al. 2012):

i. Inguinal Lymphadenectomy (IL) ii. Ilio-inguinal Lymphadenectomy (I-IL) iii. Variable use of either IL or I-IL surgery.

Some larger melanoma centres have an institutional policy that all patients have either IL or I-IL for metastatic inguinal node involvement. Nearly all centres would agree that patients with pelvic LN involvement without distant metastatic disease should have I-IL.

Study Objectives This study aims to provide a more rational evidence base for appropriate management for metastatic melanoma in the groin LNs, through assessing the effect of the addition of ipsilateral pelvic lymphadenectomy on patient disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), morbidity, and quality of life. In addition, the study will clarify the reliability of PET (Positron Emission Tomography) / CT (Computed Tomography) scans for staging pelvic LNs, clarify morbidity differences between the operations in a balanced cohort, evaluate any health economic benefits of I-IL over IL and provide a tissue and serum resource to be used to identify biological markers of recurrence and progression after inguinal metastases.

Study Hypothesis There will be no significant difference in DFS between patients having IL or I-IL, conditional on PET/CT scan showing no evidence of pelvic disease at the time of diagnosis of groin LN metastatic melanoma.

Study Population The aim is to recruit 634 patients in 5 years who are 15 years or older with cytologically or histologically confirmed metastatic melanoma in inguinal LNs (H\&E \& IHC); specifically with no evidence of pelvic node involvement or distant spread of melanoma clinically or on PET/CT staging scans. To be eligible patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 at randomisation.

Study Treatments Eligible patients will be randomised 1:1 to undergo an IL or I-IL.

Study Design This is an international, multi-centre, phase III, non-inferiority, prospective, randomised clinical trial.

03

Conditions studied

  • Metastatic Melanoma to the Groin Lymph Nodes

Browse trials for

Keywords

  • metastatic melanoma
  • groin lymph nodes
  • surgery
  • lymphadenectomy
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be included in the study only if they meet all of the following criteria:

  1. Must be 15 and above.
  2. Have primary cutaneous melanoma or if the patient presents with stage III melanoma with no known primary tumour then a thorough search for the primary should be documented (including perineal and perianal areas)
  3. of at least 10 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI
  4. Must have one or multiple inguinal node(s) involved, or cytologically proven as melanoma. This can can be detected:

    • At the time of diagnosis;
    • Or by Ultrasound detection;
    • Or later after relapse when no Sentinel Node (SNB) was performed at the time of primary tumour management;
    • Or as a result of SNB;
    • Or at the time of regional recurrence after "false negative" SNB;
  5. Absent distant disease clinically and on PET/CT scan. (Patients must have NO further distant disease or visceral metastases)
  6. performance status must be between 0 to 2 at randomisation
  7. Whole body PET/CT scan, specifically stating there is NO evidence of pelvic lymph node involvement prior to randomisation and a CT Brain or MRI Brain scan. Scans must be performed within 6 weeks prior to randomisation.
  8. Able to provide written,
  9. Willing to return to the centre for follow up examinations and procedures, as outlined in the protocol.
  10. All patients must be randomised and undergo lymphadenectomy surgery no more than 120 days following diagnosis of inguinal LN involvement

Exclusion criteria

Exclusion Criteria:

  1. Distant disease on clinical examination or staging imaging (CT/MRI brain or whole body PET/CT scan). Scans must be performed within 6 weeks prior to randomisation
  2. Pelvic LN involvement on SNB or PET/CT scan suggestive of metastatic disease in the pelvis - criteria for diagnosis include normal size or enlarged lymph nodes (> 1 cm) with increased FDG activity on PET (SUV >3). If there are enlarged, necrotic lymph nodes FDG activity on PET is not required to be present. If unsure central review should be sought.
  3. Bilateral inguinal lymph node involvement
  4. Patients with a history of major pelvic surgery and / or regional radiotherapy at any time in the past
  5. Requiring planned radiotherapy following surgery due to macroscopic, bulky and matted nodes.
  6. Unfit for General Anaesthesia
  7. Melanoma-related operative procedures not corresponding to criteria described in the protocol
  8. Patients with prior cancers, except:

    • those with a thin \<=1 mm, regionally unrelated melanoma > 5 years ago
    • those with a good prognosis regionally unrelated cancer (>90% probability of 10 years disease specific survival)
    • other cancers diagnosed more than five years ago with no evidence of disease recurrence within this time
    • successfully treated basal cell and squamous cell skin carcinoma
    • carcinoma in-situ of the cervix
    • 1 episode of in transit melanoma > 3 years ago
  9. A medical or psychiatric condition that compromises ability to give or complete the protocol
  10. Positive urine pregnancy test for women of (+/-7 days of randomisation onto the trial)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
634 participants (estimated)

Study arms

  • Other
    Arm 1: Inguinal Lymphadenectomy

    Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes

    Procedure: Inguinal Lymphadenectomy

  • Other
    Arm 2: Ilio-inguinal Lymphadenectomy

    Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.

    Procedure: Ilio-inguinal Lymphadenectomy

Interventions

  • ProcedureInguinal Lymphadenectomy
  • ProcedureIlio-inguinal Lymphadenectomy
06

What researchers measure

Primary outcomes

  1. The primary endpoint of the study will be Disease Free Survival following lymphadenectomy, assessed after 60 months of follow-up.

    The difference between IL and I-IL surgery in DFS 5 years after randomisation

    Time frame: 60 Months

Secondary outcomes

  1. Overall Survival

    time from randomisation to death from any cause

    Time frame: 0 - 120 months

  2. Distant Disease Free Survival

    time to new distant melanoma recurrence

    Time frame: 0 - 120 Months

  3. Regional Recurrence Free Survival

    time to new regional lymph node recurrence

    Time frame: 0 - 120 Months

  4. Morbidity differences

    This includes lymphoedema, wound complications (wound infections, dehiscence/necrosis, and seroma) chronic pain, and restriction in mobility

    Time frame: Up to 120 days from lymphadenectomy, and from 0 - 120 months

  5. Quality Of Life

    Quality Of Life questionnaires completed by patients

    Time frame: 0 - 120 Months

  6. Sensitivity / specificity and positive predictive value and negative predictive value of PET/CT for pelvic disease at diagnosis of groin LN involvement by melanoma.

    The diagnostic accuracy of PET/CT and CT for detecting pelvic lymph nodes positive for metastatic melanoma as confirmed by histopathology will be assessed in the sub-group of patients screened and shown to have a positive pelvic LN on PET/CT and those patients who had negative pelvic LN on PET/CT and randomised for I-IL treatment.

    Time frame: 0 - 120 Months

  7. Resource use and utility based Quality Of Life

    Resource use will be identified from the trial case report forms, and valued according the relevant Australian Refined Diagnosis Related Groups and Medicare Benefits Schedule item numbers.The cost-effectiveness and cost-utility analyses will calculate total costs and mean per patient costs per surgical group allocation, as well as total and mean benefits per group allocation.

    Time frame: 0 - 60 Months

07

Study locations

17 sites
  • Calvary Public Hospital Bruce
    Canberra, Australian Capital Territory 2617, Australia
  • Melanoma Institute Australia - The Poche Centre
    North Sydney, New South Wales 2060, Australia
  • Sydney Adventist Hospital
    Sydney, New South Wales 2076, Australia
  • Westmead Hospital
    Sydney, New South Wales 2145, Australia
  • Royal Prince Alfred Hospital
    Sydney, New South Wales, Australia
  • Mater Hospital Brisbane
    Brisbane, Queensland 4101, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Hospital de Câncer de Barretos
    Barretos, SP 14784-400, Brazil
  • A.C. Camargo Cancer Center
    Sao Paulo, SP 01508-010, Brazil
  • Veneto Institute of Oncology - IOV
    Padova, Veneto 35128, Italy
  • Radboud University Nijmegen Medical Center
    Nijmegen, Gelderland 6525, Netherlands
  • University Medical Center Groningen
    Groningen, 9713, Netherlands
  • Institute of Oncology Ljubljana
    Ljubljana, 1000, Slovenia
  • Norfolk and Norwich University Hospital
    Norwich, Norfolk NR4 7UY, United Kingdom
  • Guy's and St Thomas's Hospitals
    London, United Kingdom
  • St George's Hospital
    London, United Kingdom
  • St Helen's and Knowsley Teaching Hospitals
    St Helens, United Kingdom
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Oct 2024, 115 months.

Of 95 phase 3 interventional studies under Melanoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 94. This study's 115 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2014
First posted
Jun 18, 2014
StartActual
Mar 2, 2015
Primary completionActual
Oct 17, 2024
CompletionActual
Oct 17, 2024
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02166788
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Collaborators
Cancer Council New South Wales, Melanoma Institute Australia
Responsible party
Sponsor
First posted
Jun 18, 2014
Start date
Mar 2, 2015
Primary completion
Oct 17, 2024
Completion
Oct 17, 2024
Last update
May 9, 2025

Study contacts

Andrew Spillane
principal investigator · The University of Sydney, Northern Clinical School

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion